Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia

for the Kanto Study Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

3 Citations (Scopus)


Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p =.01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.

Original languageEnglish
Pages (from-to)1332-1337
Number of pages6
JournalLeukemia and Lymphoma
Issue number6
Publication statusPublished - 2018 Jun 3



  • Cytogenetics
  • allogeneic
  • chronic myelomonocytic leukemia
  • hematopoietic stem transplantation
  • prognosis
  • scoring system

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this